Technology area: Biotechnology & Pharmaceuticals
22 pending office actions • 15 art units • 20 examiners • 0 of 22 (0%) have an AI response strategy ready • 10 patents granted in the last 365 days
R.P. Scherer Technologies LLC has 22 pending office actions in Biotechnology & Pharmaceuticals. The matters are distributed among 20 distinct examiners and 14 distinct art units. This reflects a broad examiner footprint with more repeated placement within technical groups, creating opportunities to identify shared art-unit issues across related matters.
SKOKO III, JOHN JOSEPH is the busiest examiner, with 2 pending matters. The concentration is limited relative to the full docket, so it does not define the portfolio’s prosecution profile. Counsel may combine portfolio-level review of recurring technology issues with individualized examiner analysis.
Based on the USPTO statutory response window for each pending office action. 6 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 6 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (5%) |
| §103 only | 5 (23%) |
| §112 only | 3 (14%) |
| Double-patenting only | 1 (5%) |
| Double-patenting + other | 8 (36%) |
| Multi-statute (no §101) | 3 (14%) |
| No statute on record | 1 (5%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SKOKO III, JOHN JOSEPH | 2 | 53.0% | +55.2% |
| KASSA, TIGABU | 2 | 36.7% | +27.9% |
| WEEKS, GLORIA R | 1 | 70.4% | +12.4% |
| VU, JAKE MINH | 1 | 41.0% | +27.0% |
| JOHNSON, DANIELLE D | 1 | 45.0% | +13.2% |
| REDDIG, PETER J | 1 | 58.0% | +40.2% |
| MELCHIOR, JAMES RYLAND | 1 | 62.2% | +39.5% |
| CRAIGO, WILLIAM A | 1 | 48.9% | +38.1% |
| ISNOR, ALEXANDRA NICOLE | 1 | 26.1% | +26.2% |
| CANELLA, KAREN A | 1 | 62.3% | +32.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18140780 | DATA ANALYSIS AND REPORTING SYSTEMS AND METHODS | COLEMAN, CHARLES P. | 81d overdue |
| 19239174 | TWO PART ROTARY DIE ENCAPSULATION SYSTEM | WEEKS, GLORIA R | 29d |
| 18516302 | Softgel Capsule and Method of Marking a Softgel Capsule | ISNOR, ALEXANDRA NICOLE | 35d |
| 18195849 | METHOD OF DIFFERENTIATION OF PLURIPOTENT STEM CELLS TO RETINAL PIGMENT EPITHELIUM CELLS | MONTANARI, DAVID A | — |
| 17594677 | MINI SOFTGEL NAPROXEN COMPOSITION | BABSON, NICOLE PLOURDE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18516295 | Softgel Capsule and Method of Marking a Softgel Capsule | KASSA, TIGABU | 1d overdue |
| 19239174 | TWO PART ROTARY DIE ENCAPSULATION SYSTEM | WEEKS, GLORIA R | 29d |
| 18516302 | Softgel Capsule and Method of Marking a Softgel Capsule | ISNOR, ALEXANDRA NICOLE | 35d |
| 18908883 | METHOD TO RELIEVE STRESS IN CAPSULE SHELLS TO REDUCE PROPENSITY TO BREAK | VU, JAKE MINH | — |
| 18802287 | ENTERIC SOFTGEL CAPSULES | JOHNSON, DANIELLE D | — |
| 18621926 | ANTIBODY SPECIFIC FOR MUCIN-1 AND METHODS OF USE THEREOF | REDDIG, PETER J | — |
| 18579065 | Methods of Using Antibody-Drug-Conjugates | SKOKO III, JOHN JOSEPH | — |
| 18578690 | Tumor-Associated Calcium Signal Transducer 2 (TACSTD2) Antibody-Maytansine Conjugates and Methods of Use Thereof | MELCHIOR, JAMES RYLAND | — |
| Art Unit | Apps |
|---|---|
| 1619 | 5 |
| 1643 | 3 |
| 1615 | 2 |
| 3731 | 1 |
| 1618 | 1 |
| 1617 | 1 |
| 1646 | 1 |
| 1644 | 1 |
| 1611 | 1 |
| 1624 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19239174 | TWO PART ROTARY DIE ENCAPSULATION SYSTEM | WEEKS, GLORIA R | 3731 | §102§103 | Final Rejection | 29d | Pending | Jun 16, 2025 |
| 18908883 | METHOD TO RELIEVE STRESS IN CAPSULE SHELLS TO REDUCE PROPENSITY TO BREAK | VU, JAKE MINH | 1618 | DP | Non-Final OA | — | Pending | Oct 08, 2024 |
| 18802287 | ENTERIC SOFTGEL CAPSULES | JOHNSON, DANIELLE D | 1617 | §112Other | Non-Final OA | — | Pending | Aug 13, 2024 |
| 18621926 | ANTIBODY SPECIFIC FOR MUCIN-1 AND METHODS OF USE THEREOF | REDDIG, PETER J | 1646 | Other | Non-Final OA | — | Pending | Mar 29, 2024 |
| 18579065 | Methods of Using Antibody-Drug-Conjugates | SKOKO III, JOHN JOSEPH | 1643 | §102§103§112DP | Non-Final OA | — | Pending | Jan 12, 2024 |
| 18578690 | Tumor-Associated Calcium Signal Transducer 2 (TACSTD2) Antibody-Maytansine Conjugates and Methods of Use Thereof | MELCHIOR, JAMES RYLAND | 1644 | §112Other | Non-Final OA | — | Pending | Jan 11, 2024 |
| 18575474 | SOFTGEL CAPSULE | CRAIGO, WILLIAM A | 1615 | §103 | Final Rejection | — | Pending | Dec 29, 2023 |
| 18516295 | Softgel Capsule and Method of Marking a Softgel Capsule | KASSA, TIGABU | 1619 | §103 | Final Rejection | 1d overdue | Pending | Nov 21, 2023 |
| 18516302 | Softgel Capsule and Method of Marking a Softgel Capsule | ISNOR, ALEXANDRA NICOLE | 1611 | §103DP | Non-Final OA | 35d | Pending | Nov 21, 2023 |
| 18384707 | Anti-CD25 Antibody-Maytansine Conjugates and Methods of Use Thereof | CANELLA, KAREN A | 1643 | §103DP | Non-Final OA | — | Pending | Oct 27, 2023 |
| 18276432 | Branched Linkers for Antibody-Drug Conjugates and Methods of Use Thereof | MOORE, SUSANNA | 1624 | §112DP | Non-Final OA | — | Pending | Aug 08, 2023 |
| 18208635 | ENTERIC BISACODYL SOFTGEL CAPSULE | KASSA, TIGABU | 1619 | §103 | Final Rejection | — | Pending | Jun 12, 2023 |
| 18195849 | METHOD OF DIFFERENTIATION OF PLURIPOTENT STEM CELLS TO RETINAL PIGMENT EPITHELIUM CELLS | MONTANARI, DAVID A | 1632 | §102§112 | Final Rejection | — | Pending | May 10, 2023 |
| 18036207 | DELAYED RELEASE SOFTGEL CAPSULES | MITCHELL, EDWIN COLEMAN | 1619 | §103DP | Non-Final OA | 43d | Pending | May 10, 2023 |
| 18140780 | DATA ANALYSIS AND REPORTING SYSTEMS AND METHODS | COLEMAN, CHARLES P. | 3683 | §101 | Non-Final OA | 81d overdue | Pending | Apr 28, 2023 |
| 18300905 | SYSTEMS AND METHODS FOR PROVIDING OPTIMAL PROCESS PARAMETERS FOR FLUID BED GRANULATION SYSTEMS | CALLE, ANGEL JAVIER | 2189 | §103 | Non-Final OA | — | Pending | Apr 14, 2023 |
| 17910999 | SOFTGEL CAPSULES | WERTZ, ASHLEE ELIZABETH | 1612 | §112 | Final Rejection | — | Pending | Sep 12, 2022 |
| 17772695 | SUPPOSITORY CAPSULE | BASQUILL, SEAN M | 1614 | §103 | Final Rejection | — | Pending | Apr 28, 2022 |
| 17767523 | NON-ANIMAL SOFTGEL CAPSULE FORMULATIONS, METHODS OF PREPARATION, AND METHODS OF USE THEREOF | MATTISON, LORI K | 1619 | §103DP | Non-Final OA | — | Pending | Apr 08, 2022 |
| 17582616 | MINI SOFTGEL NAPROXEN COMPOSITION | TCHERKASSKAYA, OLGA V | 1615 | §103§112DP | Final Rejection | 31d overdue | Pending | Jan 24, 2022 |
| 17594677 | MINI SOFTGEL NAPROXEN COMPOSITION | BABSON, NICOLE PLOURDE | 1619 | §103§112 | Non-Final OA | — | Pending | Oct 26, 2021 |
| 17423796 | Glycoside-Containing Peptide Linkers for Antibody-Drug Conjugates | SKOKO III, JOHN JOSEPH | 1643 | §103DP | Non-Final OA | — | Pending | Jul 16, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialR.P. Scherer Technologies LLC has 22 pending office actions as of October 2026, spread across 15 art units and 20 examiners.
John Joseph Skoko III has the most, with 2 of R.P. Scherer Technologies LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
